Loading...

Sanofi’s avalglucosidase alfa, for Pompe disease, receives Promising Innovative Medicine designation[1]

Print Friendly, PDF & Email

READING, ENGLAND – 29 September 2020 – Sanofi announced today that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Promising Innovative Medicine (PIM) designation for avalglucosidase alfa in the treatment of Pompe disease. [1] PIM designations are given to medicinal products that are likely to […]